EPT 100: Geranium Oil for the Relief of Neuropathic Pain

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Alok K. Gupta, Pennington Biomedical Research Center
ClinicalTrials.gov Identifier:
NCT01007747
First received: November 3, 2009
Last updated: June 19, 2013
Last verified: June 2013

November 3, 2009
June 19, 2013
November 2008
June 2011   (final data collection date for primary outcome measure)
Pain relief [ Time Frame: 3 times in 30 to 60 minutes post-application ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01007747 on ClinicalTrials.gov Archive Site
Response to therapy at 30 to 60 minutes, they will be asked to apply the oil to painful area daily [ Time Frame: Daily over 1 week ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
EPT 100: Geranium Oil for the Relief of Neuropathic Pain
EPT 100: Geranium Oil for the Relief of Neuropathic Pain

The purpose of this study is to determine if Geranium oil will relieve a variety of neuropathic pain and some pain relief will last more than 48 hours.

EPT 100 study is designed to identify the percentage of people who experience neuropathic pain relief from topical geranium oil from Reunion Island, determine which neuropathic pain conditions respond best and define the time course of the pain relief.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Neuropathic Pain
Other: Geranium oil
Daily topical application over neuropathic pain
Experimental: Geranium oil
Intervention: Other: Geranium oil
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
166
October 2011
June 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 years of age or oler
  • Neuralgia or neuropathy with daily pain
  • At least moderate intensity pain
  • Signed informed consent

Exclusion Criteria:

  • Pregnant or nursing
  • Known allergies to geranium oil or geranium oil fractions
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01007747
PBRC21033
No
Alok K. Gupta, Pennington Biomedical Research Center
Pennington Biomedical Research Center
Not Provided
Not Provided
Pennington Biomedical Research Center
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP